In early autoimmune neuroinflammation, interferon (IFN)g and its upregulation of the 18 immunoproteasome (iP) is pathologic. However, during chronic multiple sclerosis (MS), IFNg has 19 protective properties and, the role of the iP remains to be fully elucidated. Here, we demonstrated 20 that IFNg signaling in regional astrocytes induces the iP and protects the CNS during 21 autoimmunity. In MS tissue, iP expression was enhanced in spinal cord compared to brainstem 22 lesions, which correlated with a decrease in oxidative stress. In vitro, IFNg stimulation enhanced 23 iP expression, reduced reactive oxygen species burden, and decreased oxidatively damaged and 24 poly-ubiquitinated protein accumulation preferentially in human spinal cord astrocytes, which was 25 abrogated with the use of the iP inhibitor, ONX 0914. During the chronic phase of an MS animal 26 model, experimental autoimmune encephalomyelitis (EAE), ONX 0914 treatment exacerbated 27 disease and led to increased oxidative stress and poly-ubiquitinated protein build-up. Finally, mice 28 with astrocyte-specific loss of the IFNg receptor exhibited worsened chronic EAE associated with 29 reduced iP expression, enhanced lesion size and oxidative stress and poly-ubiquitinated protein 30 accumulation in astrocytes. Taken together, our data reveal a protective role for IFNg in chronic 31 neuroinflammation and identify a novel function of the iP in astrocytes during CNS autoimmunity. 32 33 34 Multiple sclerosis (MS) is the most common chronic inflammatory and 35 neurodegenerative disease of the central nervous system (CNS) (1). During the 36 pathogenesis of MS, there is immune cell infiltration, demyelination, and reactive gliosis 37
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relatively limited (6). Thus, it is not surprising that the 12 immunomodulatory, FDA-48 approved therapies for RRMS (7) have limited effectiveness in SPMS and PPMS patients 49 (8-10) and in some cases have resulted in patient worsening (11, 12) . Indeed, neutralizing 50 specific inflammatory cytokines in MS patients resulted in exacerbated neurological 51 deficits (13) without reducing lesion load (14), suggesting a complex, and potentially 52 protective role for inflammatory cytokines during chronic MS that is not fully understood. 53
Astrocytes are the most numerous cell type in the CNS and are found in and 54 around MS lesions. Although they have long been considered bystanders of MS 55 pathology, their role in the initiation and resolution of disease is becoming more 56 appreciated (15, 16) . During MS and experimental autoimmune encephalomyelitis (EAE), 57 exacerbated disease compared to WT animals (47-55). Further, only mice with intact IFNg 81 signaling were able to recover from EAE (56). Using a signaling deficient dominant-82 negative Ifngr1 driven by the Gfap promotor, the protective effects of IFNg signaling during 83 chronic EAE was linked to astrocytes (57). While follow-up studies indicate these effects 84 may be due to altered cytokine release influencing microglia (58), the astrocyte-specific 85 mechanisms of IFNg-mediated protection are not defined. 86
Our study demonstrating that IFNg signaling in regional astrocytes mediates 87 protection during chronic autoimmune neuroinflammation through induction of the 88 immunoproteasome (iP) has clear clinical applications. Inefficacy of first line 89 immunomodulatory therapies in chronic-progressive MS patients demands the 90 identification of novel therapeutic approaches. Since the iP has a critical role in T cell 91 activation during the early, inflammatory phases of MS and EAE, which is thought to drive 92 pathogenesis, and proteasome inhibitors have recently been utilized for the treatment of 93 certain types of cancer, proteasome inhibitors are being discussed as a potential 94 treatment strategy for MS patients (59, 60) . Given that the role of the iP in the CNS is 95 largely unexplored and may have a neuroprotective function in astrocytes, further 96 understanding of the iP is of great importance and incredibly timely (61). Our study 97 suggests that the iP is a potential mediator of protection during chronic CNS autoimmunity 98 following astrocyte IFNg signaling and identification of an endogenous inhibitor of the iP 99 might represent a novel therapeutic target that would benefit chronic MS patients with 100 specific patterns of neuroinflammation. In summary, these findings advance our 101 understanding of the astrocyte adaptive immune response during chronic CNS 102 autoimmunity, identify regionally distinct protective role for astrocytes, and suggest that 103 defining upstream targets that modulate iP expression would facilitate the identification of 104 new targets for the treatment of SPMS and PPMS patients. 105
106 Results 
107
In several neurodegenerative diseases, the iP is known to clear reactive oxygen 108 species (ROS) and degrade poly-ubiquitinated proteins (62-64); and, there is evidence 109 that the iP may be dysregulated during MS and experimental autoimmune 110 encephalomyelitis (EAE), an animal model of MS (64-66). Additionally, astrocytes have 111 been implicated in modulating neuroinflammation and neurodegeneration (67-69); 112 however, the role of the astrocyte iP during MS and EAE has not yet been fully elucidated. 113
To determine the role of the iP in MS brain, we evaluated the mRNA expression of genes 114 associated with the classical proteasome (PSMB7) and the iP (PSMB8) in previously 115 published MS patient tissue microarray data (70). Strikingly, we found PSMB7 to be 116 significantly downregulated while PSMB8 was significantly increased in white matter 117 lesions (WML) compared to controls and normal appearing white matter (NAWM) ( Figure  118 1, A and B). Although lesions in the brainstem and spinal cord are common and result in 119 pronounced disability during MS (71, 72) and EAE (73), relatively little is known about 120 lesion pathology in these regions. Thus, we examined NAWM and areas of demyelination 121 in the brainstem ( Figure 1C ) and spinal cord ( Figure 1D ) of MS patients, labeling an iP 122 subunit (LMP7) and an indicator of oxidative stress (PRDX6) within astrocytes by 123 immunohistochemistry (IHC). In WMLs, there was an inverse relationship between LMP7 124 and PRDX6 specifically in the spinal cord ( Figure 1E ), suggesting that the iP may play a 125 role in reducing oxidative stress in MS lesions and that there may be a difference in iP 126 expression and/or function in regional astrocytes. 127
Astrocytes are regionally heterogeneous in morphology, gene expression, and 128 function during physiological and pathological conditions (74, 75). Since the iP is readily 129 induced by IFNg, which is present at all stages of MS (34, 76), and astrocytes are in and 130 around MS lesions and respond to IFNg, we further explored heterogenous regulation of 131 the astrocyte iP between the brainstem and spinal cord driven by IFNg. Using primary 132 human astrocytes from the brainstem and spinal cord (Supplemental Figure 1 ), we 133 analyzed iP transcript levels following IFNg stimulation over the course of 48 h. 134
Expression levels of the iP subunits PSMB8, PSMB9, and PSMB10 increased in spinal 135 cord astrocytes compared to those in brainstem-derived astrocytes, with the most robust 136 transcript upregulation occurring at 48 h (Figure 2A ). Of note, there was no appreciable 137 change in constitutive proteasome subunit transcript in either region following IFNg 138 stimulation (Supplemental Figure 2 ). We confirmed regional differences in iP expression 139 in astrocytes at the protein level by analyzing protein lysate from human brainstem and 140 spinal cord astrocytes incubated with and without IFNg ( Figure 2 , B and C). Although IFNg 141 expression is robust and perpetuates acute inflammation in both MS and EAE, it is still 142 present during chronic disease, albeit at lower levels (77, 78). To determine the regional 143 sensitivity of astrocytes to IFNg stimulation, we measured the transcript expression levels 144 of iP subunits following an IFNg dose titration over 24 or 48 h. Interestingly, compared to 145 those from the brainstem, all of the iP subunits were upregulated specifically in astrocytes 146 from the spinal cord following exposure to low concentrations of IFNg after 48 h ( Figure  147 2D). To determine if regional differences in astrocyte iP expression were present in vivo 148 during neuroinflammation, we induced EAE in Ifngr1 fl/fl Tie2-Cre + mice, in which the IFNg 149 receptor (IFNGR1) is deleted from endothelial cells of the blood-brain barrier (79, 80), 150 conferring inflammation in both the brainstem and spinal cord and maintaining genetically 151 WT astrocytes. Signs of both classical EAE, primarily affecting the spinal cord, and 152 atypical EAE, which affects the hindbrain, was monitored (Supplemental Figure 3A ) (81, 153 82). To determine if iP expression is regionally distinct, we first confirmed that lesion size 154 between the brainstem and spinal cord was consistent in Ifngr1 fl/fl Tie2-Cre + mice 155 (Supplemental Figure 3B ). While the average lesion size was similar between regions in 156 Ifngr1 fl/fl Tie2-Cre + mice, iP expression in spinal cord astrocytes was significantly 157 increased compared to those in the brainstem (Supplemental Figure 3C ). These data 158 demonstrate that both in human astrocytes and in an in vivo model of regional 159 autoimmune neuroinflammation, astrocyte iP expression is preferentially upregulated by 160
IFNg in spinal cord astrocytes compared to those in the brainstem. This suggests that in 161 the spinal cord, the iP is potentially a primary astrocyte-mediated protection mechanism 162 during neuroinflammation and that brainstem astrocytes may engage alternate pathways. 163
The best known function of the iP is its role in antigen processing; however, since 164 astrocytes present little or no antigen (83-85), alternate functions of the iP were examined, 165 namely, clearance of ROS and oxidatively damaged and poly-ubiquitinated proteins (86). 166
To determine the role of the iP in astrocyte viability and ROS clearance, we treated 167 regional human astrocytes with or without IFNg and a specific inhibitor of the iP, ONX 168 0914 (87-89). Following iP inhibition, an increase in caspase activity was observed only 169 in spinal cord astrocytes compared to media treatment, which was significantly enhanced 170 compared to those from the brainstem ( Figure 3A ). Next, we observed an overall increase 171 in cellular ROS in astrocytes treated with ONX 0914, with enhanced ROS in spinal cord 172 astrocytes compared to brainstem astrocytes. Interestingly, in cells treated only with IFNg, 173 astrocytes from the spinal cord produced less ROS than brainstem-derived astrocytes 174 ( Figure 3B ). Assessment of oxidative protein damage revealed an increase in spinal cord 175 versus brainstem astrocytes following iP inhibition. There was also a treatment effect in 176 spinal cord astrocytes with a reduction in oxidatively damaged proteins following IFNg Interferong is primarily pro-inflammatory in acute stages of MS and EAE (78); 224 however, there is evidence to suggest that in chronic MS and EAE, IFNg has protective 225 functions (37, 38, 81). In this study, we confirm these findings and demonstrate that IFNg 226 signaling in astrocytes leads to the upregulation of the iP, which dampens chronic EAE 227 severity. Our studies indicate that IFNg-mediated upregulation of the iP leads to 228 preservation of astrocyte integrity by reducing ROS, degrading oxidatively damaged and 229 poly-ubiquitinated proteins. In vivo, IFNgR signaling was critical for iP upregulation in 230 astrocytes, which was associated with a reduction in lesion size and disease severity 231 during chronic EAE. Further, studies using postmortem MS tissue, in vitro astrocytes, and 232 models of EAE showed enhanced iP expression in the spinal cord compared to the 233 brainstem, suggesting that spinal cord astrocytes more readily upregulate the iP upon 234
IFNg stimulation, leading to enhanced region-specific protection during CNS 235 autoimmunity. 236
These findings reveal the importance of IFNg signaling and its role in astrocyte iP 237 regulation during chronic stages of neurodegenerative disease, and they highlight the 238 stage-specific roles of IFNg during MS and EAE. Indeed, previous studies have shown 239 that iP inhibition during acute disease leads to EAE amelioration by dampening peripheral 240 immune responses (90, 91). Importantly, it has recently been shown that IFNg diverts 241
OPCs from differentiating into mature oligodendrocytes to cells with antigen presenting 242 capabilities via upregulation of the iP, a critical immune-priming process during acute EAE 243 (92). However, during chronic EAE, IFNgR signaling specifically in astrocytes was 244 beneficial, resulting in smaller lesions, less demyelination and a reduction in EAE severity 245 in control mice compared to those with astrocytes deficient in IFNgR (81). Here, we extend 246 those findings by demonstrating that upregulation of the iP is one potential mechanism 247 by which IFNg signaling protects the CNS during chronic neuroinflammation. We These findings broaden our understanding of astrocyte heterogeneity in the CNS. 269
Although regional heterogeneity of astrocytes in neurophysiologic functions (18, 19, 105) 270 and in many disease models (106-108), including EAE (75, 109, 110), has been 271 appreciated, there are no studies to date that have described a regional role for the iP in 272 the CNS. However, a regional difference in Type I IFN signaling in astrocytes has been 273 described (111). Here, we expand on those findings, demonstrating a regional increase 274 in iP expression preferentially in spinal cord astrocytes compared to those from the 275 brainstem in response to IFNg. We show that this increase in iP expression in spinal cord 276 astrocytes is protective, as inhibition of the iP results in reduced astrocyte viability, 277 increased ROS production, and accumulation of damaged proteins. This diverse 278 astrocytic response is critical in healthy tissue preservation and support as it minimizes 279 prolonged CNS exposure to cytotoxic inflammation. Indeed, ablation of astrocytes 280 following several types of CNS injury leads to sustained inflammation, impaired blood-281 brain barrier repair, and increased neurodegeneration (20-29). Thus, the survival of 282 astrocytes following damage is key in CNS recovery. Taken together, our data suggests 283 that the astrocyte iP may be a key mechanism of protection in the spinal cord while other 284 distinct CNS regions may rely on alternate pathways to facilitate damage control and 285 recovery during chronic neurodegeneration and CNS inflammation. 
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Sections were blocked with 3% goat serum and 0.01% Triton X-100 (Sigma-Aldrich) for 1 h at 305 room temperature and then exposed to antibodies specific for human LMP7 (ThermoFisher 306 Scientific; MA5-15890) or PRDX6 (Abcam; ab59543) and GFAP (Invitrogen; 13-0300) for 4 days 307 at 4°C. Sections were then washed with PBS-Tween 20 and secondary antibodies conjugated to 308 Alexa Fluor 488 or 555 (ThermoFisher Scientific) were applied for 1 h at room temperature.
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Sections were then treated with 0.3% sudan black in 70% ethanol for 3 min, analyzed using the Astrocyte response to IFN-gamma limits IL-6-mediated microglia activation and 596 
